vs
Side-by-side financial comparison of ASTROTECH Corp (ASTC) and IGC Pharma, Inc. (IGC). Click either name above to swap in a different company.
IGC Pharma, Inc. is the larger business by last-quarter revenue ($191.0K vs $148.0K, roughly 1.3× ASTROTECH Corp). IGC Pharma, Inc. runs the higher net margin — -953.4% vs -2653.4%, a 1700.0% gap on every dollar of revenue. On growth, ASTROTECH Corp posted the faster year-over-year revenue change (-43.3% vs -53.6%). IGC Pharma, Inc. produced more free cash flow last quarter ($-2.1M vs $-4.0M). Over the past eight quarters, IGC Pharma, Inc.'s revenue compounded faster (-19.0% CAGR vs -40.2%).
Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.
IGC Pharma, Inc. is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative cannabinoid-derived therapeutics. Its core pipeline targets treatments for neurodegenerative conditions, pain and rare diseases, with primary operations in North America and ongoing global market expansion.
ASTC vs IGC — Head-to-Head
Income Statement — Q2 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $148.0K | $191.0K |
| Net Profit | $-3.9M | $-1.8M |
| Gross Margin | 5.4% | 51.8% |
| Operating Margin | -2635.8% | -1517.8% |
| Net Margin | -2653.4% | -953.4% |
| Revenue YoY | -43.3% | -53.6% |
| Net Profit YoY | 2.0% | -6.1% |
| EPS (diluted) | — | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.0K | — | ||
| Q3 25 | $297.0K | $191.0K | ||
| Q2 25 | $220.0K | $328.0K | ||
| Q1 25 | $534.0K | — | ||
| Q4 24 | $261.0K | $257.0K | ||
| Q3 24 | — | $412.0K | ||
| Q2 24 | — | $272.0K | ||
| Q1 24 | — | $295.0K |
| Q4 25 | $-3.9M | — | ||
| Q3 25 | $-3.5M | $-1.8M | ||
| Q2 25 | $-2.9M | $-1.6M | ||
| Q1 25 | $-3.6M | — | ||
| Q4 24 | $-4.0M | $-1.8M | ||
| Q3 24 | — | $-1.7M | ||
| Q2 24 | — | $-2.4M | ||
| Q1 24 | — | $-2.9M |
| Q4 25 | 5.4% | — | ||
| Q3 25 | 63.3% | 51.8% | ||
| Q2 25 | 33.6% | 47.0% | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 59.4% | 40.5% | ||
| Q3 24 | — | 48.1% | ||
| Q2 24 | — | 59.9% | ||
| Q1 24 | — | 58.0% |
| Q4 25 | -2635.8% | — | ||
| Q3 25 | -1190.6% | -1517.8% | ||
| Q2 25 | -1326.4% | -580.8% | ||
| Q1 25 | -724.2% | — | ||
| Q4 24 | -1655.6% | -730.7% | ||
| Q3 24 | — | -427.2% | ||
| Q2 24 | — | -880.9% | ||
| Q1 24 | — | -735.6% |
| Q4 25 | -2653.4% | — | ||
| Q3 25 | -1166.7% | -953.4% | ||
| Q2 25 | -1331.8% | -487.5% | ||
| Q1 25 | -680.3% | — | ||
| Q4 24 | -1536.0% | -711.7% | ||
| Q3 24 | — | -416.7% | ||
| Q2 24 | — | -874.3% | ||
| Q1 24 | — | -978.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.02 | ||
| Q2 25 | — | $-0.02 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $1.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.5M | $8.1M |
| Total Assets | $19.7M | $9.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | — | ||
| Q3 25 | $11.3M | $1.1M | ||
| Q2 25 | $15.1M | $454.0K | ||
| Q1 25 | $18.1M | — | ||
| Q4 24 | $21.5M | $470.0K | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | — | $1.8M | ||
| Q1 24 | — | $1.2M |
| Q4 25 | $15.5M | — | ||
| Q3 25 | $19.1M | $8.1M | ||
| Q2 25 | $22.1M | $6.1M | ||
| Q1 25 | $24.8M | — | ||
| Q4 24 | $28.1M | $6.3M | ||
| Q3 24 | — | $7.4M | ||
| Q2 24 | — | $7.9M | ||
| Q1 24 | — | — |
| Q4 25 | $19.7M | — | ||
| Q3 25 | $23.2M | $9.7M | ||
| Q2 25 | $27.0M | $7.9M | ||
| Q1 25 | $27.5M | — | ||
| Q4 24 | $31.0M | $9.1M | ||
| Q3 24 | — | $10.4M | ||
| Q2 24 | — | $10.6M | ||
| Q1 24 | — | $9.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $-2.1M |
| Free Cash FlowOCF − Capex | $-4.0M | $-2.1M |
| FCF MarginFCF / Revenue | -2671.6% | -1109.4% |
| Capex IntensityCapex / Revenue | 277.7% | 15.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-14.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-3.9M | $-2.1M | ||
| Q2 25 | $-2.4M | $-1.4M | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.0M | — | ||
| Q3 24 | — | $-996.0K | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-526.0K |
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-4.4M | $-2.1M | ||
| Q2 25 | $-2.7M | $-1.4M | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | $-3.4M | — | ||
| Q3 24 | — | $-1.0M | ||
| Q2 24 | — | $-1.8M | ||
| Q1 24 | — | $-541.0K |
| Q4 25 | -2671.6% | — | ||
| Q3 25 | -1476.1% | -1109.4% | ||
| Q2 25 | -1231.4% | -431.4% | ||
| Q1 25 | -728.1% | — | ||
| Q4 24 | -1288.5% | — | ||
| Q3 24 | — | -248.8% | ||
| Q2 24 | — | -658.1% | ||
| Q1 24 | — | -183.4% |
| Q4 25 | 277.7% | — | ||
| Q3 25 | 150.8% | 15.2% | ||
| Q2 25 | 158.2% | 2.4% | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 122.2% | — | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | — | 14.0% | ||
| Q1 24 | — | 5.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
